De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference
Por:
Colmenero, J, Tabrizian, P, Bhangui, P, Pinato, D, Rodriguez-Peralvarez, M, Sapisochin, G, Bhoori, S, Pascual, S, Senzolo, M, Al-Adra, D, Herrero, J, Petrowsky, H, Dawson, L, Hosni, A, Kutzke, J, Gastaca, M and Watt, K
Publicada:
1 ene 2022
Resumen:
De novo malignancies (DNMs) following liver transplantation (LT) have been reported as 1 of the major causes of late mortality, being the most common cause of death in the second decade after LT. The overall incidence of DNMs is reported to be in the range of 3.1% to 14.4%, and the incidence is 2- to 3-fold higher in transplant recipients than in age- and sex-matched healthy controls. Long-term immunosuppressive therapy, which is the key in maintaining host tolerance and achieving good long-term outcomes, is known to contribute to a higher risk of DNMs. However, the incidence and type of DNM also depends on different risk factors, including patient demographics, cause of the underlying chronic liver disease, behavior (smoking and alcohol abuse), and pre-existing premalignant conditions. The estimated standardized incidence ratio for different DNMs is also variable. The International Liver Transplantation Society-Spanish Society of Liver Transplantation Consensus Conference working group on DNM has summarized and discussed the current available literature on epidemiology, risk factors, management, and survival after DNMs. Recommendations for screening and surveillance for specific tumors, as well as immunosuppression and cancer-specific management in patients with DNM, are summarized.
Filiaciones:
Colmenero, J:
Univ Barcelona, CIBERehd, Hosp Clin Barcelona, Liver Transplantat,Liver Unit,IDIBAPS, Barcelona, Spain
Tabrizian, P:
Icahn Sch Med Mt Sinai, New York, NY 10029 USA
Bhangui, P:
Medanta Medicity, Inst Liver Transplantat & Regenerat Med, Delhi Ncr, India
Pinato, D:
Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England
Rodriguez-Peralvarez, M:
Univ Cordoba, CIBERehd, IMIBIC, Dept Hepatol & Liver Transplantat,Hosp Univ Reina, Cordoba, Spain
Sapisochin, G:
Univ Toronto, Toronto Gen Hosp, Multiorgan Transplant Program, Toronto, ON, Canada
Bhoori, S:
Fdn IRCCS Ist Nazl Tumori Milano, HPB Surg Hepatol & Liver Transplantat, Milan, Italy
:
HGU Alicante, ISABIAL, Liver Unit, CIBERehd, Alicante, Spain
Senzolo, M:
Univ Hosp Padua, Multivisceral Transplant Unit, Padua, Italy
Al-Adra, D:
Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
Herrero, J:
Clin Univ Navarra, CIBERehd, IdiSNA, Liver Unit, Pamplona, Spain
Petrowsky, H:
Univ Hosp Zurich, Dept Surg & Transplantat, Swiss HPB & Transplantat Ctr, Zurich, Switzerland
Dawson, L:
Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
Hosni, A:
Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
Kutzke, J:
Mayo Clin, Dept Pharm, Rochester, MN 55905 USA
Gastaca, M:
Univ Basque Country, Biocruces Bizkaia Hlth Res Inst, Cruces Univ Hosp, Bilbao, Spain
Watt, K:
Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA
Bronze
|